Skip to main content
Top
Published in: Social Psychiatry and Psychiatric Epidemiology 4/2013

01-04-2013 | Original Paper

Description of long-term polypharmacy among schizophrenia outpatients

Authors: Jaana T. Suokas, Jaana M. Suvisaari, Jari Haukka, Pasi Korhonen, Jari Tiihonen

Published in: Social Psychiatry and Psychiatric Epidemiology | Issue 4/2013

Login to get access

Abstract

Objective

This large nationwide study describes the prevalence and predictors of long-term antipsychotic polypharmacy among patients with schizophrenia.

Methods

A register-based longitudinal study of all people in Finland, who had at least one hospitalization due to schizophrenia during the years 2000–2007 and who were alive on March 1, 2007. Entry to the cohort was defined from the first hospitalization for schizophrenia during the years 2000–2007, and the date of assessment of antipsychotic polypharmacy was March 1, 2007. We studied separately chronic (N = 8,037) and recent onset (N = 8,046) schizophrenia patients. Antipsychotic polypharmacy was defined as overlapping of two or more filled prescriptions of antipsychotics for over 60 days.

Results

In a total 16,083 patients with schizophrenia the prevalence of antipsychotic polypharmacy was 46.2 % (N = 7,436, mean age 47.5 years, male 55 %). The longer the duration of schizophrenia, the more common the antipsychotic polypharmacy. Long index hospitalization and being male significantly associated with antipsychotic polypharmacy among all schizophrenia patients. Especially, in chronic schizophrenia patients, the previous use of benzodiazepine like agents was associated with antipsychotic polypharmacy, but the use of antidepressants associated with less frequent antipsychotic polypharmacy.

Conclusions

Antipsychotic polypharmacy was widely prevalent among patients with schizophrenia and it was associated with long hospitalizations and long duration of illness. Benzodiazepine use was associated with increased risk and antidepressant use with decreased risk of antipsychotic polypharmacy when the effect of other clinical and socioeconomic factors was adjusted. Research is needed of risks and benefits of antipsychotic polypharmacy and augmentation of antipsychotic with other psychoactive drugs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, William Keller W (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36(1):71–93PubMedCrossRef Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, William Keller W (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36(1):71–93PubMedCrossRef
3.
go back to reference Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric Association, Steering Committee on Practice Guidelines (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161(2 Suppl):1–56PubMed Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric Association, Steering Committee on Practice Guidelines (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161(2 Suppl):1–56PubMed
5.
go back to reference Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covel NH (2011) Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 168:702–708PubMedCrossRef Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covel NH (2011) Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 168:702–708PubMedCrossRef
7.
go back to reference Stahl SM (2002) Antipsychotic polylpharmacy: squandering precious resources? J Clin Psychiatry 63:93–94PubMedCrossRef Stahl SM (2002) Antipsychotic polylpharmacy: squandering precious resources? J Clin Psychiatry 63:93–94PubMedCrossRef
8.
go back to reference Correll CU, Rummel-Klulge C, Corves C, Kane JM, Leucht S (2009) Antipsychotic combination vs. monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35(2):443–457PubMedCrossRef Correll CU, Rummel-Klulge C, Corves C, Kane JM, Leucht S (2009) Antipsychotic combination vs. monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35(2):443–457PubMedCrossRef
9.
go back to reference Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, Kim YS (2008) Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69(5):720–721PubMedCrossRef Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, Kim YS (2008) Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69(5):720–721PubMedCrossRef
10.
go back to reference Fleschhacker WW, Heikkinen ME, Olie J-P, Landsberg W, Dewaele P, McQuade RD, Loze J-Y, Hennicken D, Kerselaers WS (2010) Effects on adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13:1115–1125CrossRef Fleschhacker WW, Heikkinen ME, Olie J-P, Landsberg W, Dewaele P, McQuade RD, Loze J-Y, Hennicken D, Kerselaers WS (2010) Effects on adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13:1115–1125CrossRef
11.
go back to reference McCue RE, Waheed R, Urcuyo L (2003) Polypharmacy in patients with schizophrenia. J Clin Psychiatry 64:984–989PubMedCrossRef McCue RE, Waheed R, Urcuyo L (2003) Polypharmacy in patients with schizophrenia. J Clin Psychiatry 64:984–989PubMedCrossRef
12.
go back to reference Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC (2004) Prevalence, trends and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998–2000. J Clin Psychiatry 65:1377–1388PubMedCrossRef Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC (2004) Prevalence, trends and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998–2000. J Clin Psychiatry 65:1377–1388PubMedCrossRef
13.
go back to reference Janssen B, Weinmann S, Berger M, Gaebel W (2004) Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull 30(4):1023–1033PubMedCrossRef Janssen B, Weinmann S, Berger M, Gaebel W (2004) Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull 30(4):1023–1033PubMedCrossRef
14.
go back to reference Edlinger M, Hausmann A, Kemmler G, Kurz M, Kurzthaler I, Walch T, Walpoth M, Fleischhacker W (2005) Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr Res 77:25–34PubMedCrossRef Edlinger M, Hausmann A, Kemmler G, Kurz M, Kurzthaler I, Walch T, Walpoth M, Fleischhacker W (2005) Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr Res 77:25–34PubMedCrossRef
15.
go back to reference Faries D, Ascher-Svanum H, Zhu B, Correl C, Kane J (2005) Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotic. BMC Psychiatry 5:26PubMedCrossRef Faries D, Ascher-Svanum H, Zhu B, Correl C, Kane J (2005) Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotic. BMC Psychiatry 5:26PubMedCrossRef
16.
go back to reference Barbui C, Nose M, Mazzi MA, Thornicroft G, Schene A, Becker T, Bindman J, Leese M, Helm H, Koeter M, Weinmann S, Tansella M (2006) Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol 21(6):355–362PubMedCrossRef Barbui C, Nose M, Mazzi MA, Thornicroft G, Schene A, Becker T, Bindman J, Leese M, Helm H, Koeter M, Weinmann S, Tansella M (2006) Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol 21(6):355–362PubMedCrossRef
17.
go back to reference Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, Tapp A, Keefe RS, Rosenheck RA (2006) Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 57:1084–1101CrossRef Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, Tapp A, Keefe RS, Rosenheck RA (2006) Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 57:1084–1101CrossRef
18.
go back to reference Gilmer TP, Dolder CR, Folsom DP, Mastin W, Jeste DV (2007) Antipsychotic polypharmacy trends among Medical beneficiaries with schizophrenia in San Diego county, 1999–2004. Psychiatr Serv 58(7):1007–1010PubMedCrossRef Gilmer TP, Dolder CR, Folsom DP, Mastin W, Jeste DV (2007) Antipsychotic polypharmacy trends among Medical beneficiaries with schizophrenia in San Diego county, 1999–2004. Psychiatr Serv 58(7):1007–1010PubMedCrossRef
19.
go back to reference Megna JL, Kunwar AR, Mahlotra K, Sauro MD, Devitt PJ, Rashid A (2007) A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness. J Psychiatr Pract 13(2):129–137PubMedCrossRef Megna JL, Kunwar AR, Mahlotra K, Sauro MD, Devitt PJ, Rashid A (2007) A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness. J Psychiatr Pract 13(2):129–137PubMedCrossRef
20.
go back to reference Gören JL, Parks JJ, Ghinassi FA, Milton CG, Oldham JM, Hernandez P, Chan J, Hermann R (2008) When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf 34(10):571–582PubMed Gören JL, Parks JJ, Ghinassi FA, Milton CG, Oldham JM, Hernandez P, Chan J, Hermann R (2008) When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf 34(10):571–582PubMed
21.
go back to reference Pandurangi AK, Dalkilic A (2008) Polypharmacy with second-generation antipsychotics: a review of evidence. J Psychiatr Pract 14(6):345–367PubMedCrossRef Pandurangi AK, Dalkilic A (2008) Polypharmacy with second-generation antipsychotics: a review of evidence. J Psychiatr Pract 14(6):345–367PubMedCrossRef
22.
go back to reference Jaffe AB, Levine J (2003) Antipsychotic medication coprescribing in the large state hospital system. Pharmacoepidemiol Drug Saf 12:41–48PubMedCrossRef Jaffe AB, Levine J (2003) Antipsychotic medication coprescribing in the large state hospital system. Pharmacoepidemiol Drug Saf 12:41–48PubMedCrossRef
23.
go back to reference Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N (2003) Combination antipsychotic therapy in clinical practice. Psychiatr Serv 54(1):55–59PubMedCrossRef Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N (2003) Combination antipsychotic therapy in clinical practice. Psychiatr Serv 54(1):55–59PubMedCrossRef
24.
go back to reference Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC (2006) Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res 84:90–99PubMedCrossRef Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC (2006) Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res 84:90–99PubMedCrossRef
25.
go back to reference Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher J, Baldessarini R (2004) Multiple versus single antipsychotic agents for hospitalized psychiatric patient: case–control study of risks versus benefits. Am J Psychiatry 161:700–706PubMedCrossRef Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher J, Baldessarini R (2004) Multiple versus single antipsychotic agents for hospitalized psychiatric patient: case–control study of risks versus benefits. Am J Psychiatry 161:700–706PubMedCrossRef
26.
go back to reference Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002) Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for State Mental Health Policy. Schizophr Bull 28(1):75–84PubMedCrossRef Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002) Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for State Mental Health Policy. Schizophr Bull 28(1):75–84PubMedCrossRef
27.
go back to reference Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V (2006) Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 188:122–127PubMedCrossRef Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V (2006) Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 188:122–127PubMedCrossRef
28.
go back to reference Baandrup L, Gasse C, Jensen V, Glenthoj B, Nordentoft M, Lublin H, Fink-Jensen A, Lindhart A, Mortensen P (2010) Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case–control study. J Clin Psychiatry 71(2):103–108PubMedCrossRef Baandrup L, Gasse C, Jensen V, Glenthoj B, Nordentoft M, Lublin H, Fink-Jensen A, Lindhart A, Mortensen P (2010) Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case–control study. J Clin Psychiatry 71(2):103–108PubMedCrossRef
29.
go back to reference Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study. Lancet 374:620–627PubMedCrossRef Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study. Lancet 374:620–627PubMedCrossRef
30.
go back to reference Tiihonen J, Suokas J, Suvisaari J, Haukka J, Korhonen P (2012) Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 69(5):476–483PubMedCrossRef Tiihonen J, Suokas J, Suvisaari J, Haukka J, Korhonen P (2012) Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 69(5):476–483PubMedCrossRef
31.
go back to reference Tiihonen J, Haukka J, Haddad P, Patel M, Korhonen P (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168:603–609PubMedCrossRef Tiihonen J, Haukka J, Haddad P, Patel M, Korhonen P (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168:603–609PubMedCrossRef
33.
go back to reference Nielsen LH, Løkkegaard E, Andreasen AH, Keiding N (2008) Using prescription registries to define continuous drug use: how to fill gaps between prescriptions. Pharmacoepidemiol Drug Saf 17:384–388PubMedCrossRef Nielsen LH, Løkkegaard E, Andreasen AH, Keiding N (2008) Using prescription registries to define continuous drug use: how to fill gaps between prescriptions. Pharmacoepidemiol Drug Saf 17:384–388PubMedCrossRef
34.
go back to reference Pickar D, Vinik J, Bartko JJ (2008) Pharmacotherapy of schizophrenia patients: preponderance of off-label drug use. PLoS ONE 3(9):e3150 Pickar D, Vinik J, Bartko JJ (2008) Pharmacotherapy of schizophrenia patients: preponderance of off-label drug use. PLoS ONE 3(9):e3150
35.
go back to reference Sernyak M, Rosenheck R (2004) Clinicians’ reasons for antipsychotic coprescribing. J Clin Psychiatry 65:107–117CrossRef Sernyak M, Rosenheck R (2004) Clinicians’ reasons for antipsychotic coprescribing. J Clin Psychiatry 65:107–117CrossRef
36.
go back to reference Längle G, Steiner T, Weiser P, Schep W, Jaeger S, Pfiffner C, Frasch K, Eschweiler GW, Messer T, Croissant D, Becker T, Kilian R (2012) Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment. Acta Psychiatr Scand 125:372–381PubMedCrossRef Längle G, Steiner T, Weiser P, Schep W, Jaeger S, Pfiffner C, Frasch K, Eschweiler GW, Messer T, Croissant D, Becker T, Kilian R (2012) Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment. Acta Psychiatr Scand 125:372–381PubMedCrossRef
37.
go back to reference Perälä J, Saarni SI, Ostamo A, Pirkola S, Haukka J, Härkänen T, Koskinen S, Lönnqvist J, Suvisaari J (2008) Geographic variation and sociodemographic characteristics of psychotic disorders in Finland. Schizophr Res 106:337–347PubMedCrossRef Perälä J, Saarni SI, Ostamo A, Pirkola S, Haukka J, Härkänen T, Koskinen S, Lönnqvist J, Suvisaari J (2008) Geographic variation and sociodemographic characteristics of psychotic disorders in Finland. Schizophr Res 106:337–347PubMedCrossRef
38.
go back to reference Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU (2012) Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 138:18–28PubMedCrossRef Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU (2012) Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 138:18–28PubMedCrossRef
39.
go back to reference Terevnikov F, Stenberg J, Tiihonen J, Joffe M, Burkin M, Tchoukhine E, Joffe G (2011) Add-on mirtazapine improves depressive symptoms in schizophrenia: a douple-blind randomized placebo-controlled study with an open-label extension phase. Hum Psychopharmacol 26:188–193PubMed Terevnikov F, Stenberg J, Tiihonen J, Joffe M, Burkin M, Tchoukhine E, Joffe G (2011) Add-on mirtazapine improves depressive symptoms in schizophrenia: a douple-blind randomized placebo-controlled study with an open-label extension phase. Hum Psychopharmacol 26:188–193PubMed
Metadata
Title
Description of long-term polypharmacy among schizophrenia outpatients
Authors
Jaana T. Suokas
Jaana M. Suvisaari
Jari Haukka
Pasi Korhonen
Jari Tiihonen
Publication date
01-04-2013
Publisher
Springer-Verlag
Published in
Social Psychiatry and Psychiatric Epidemiology / Issue 4/2013
Print ISSN: 0933-7954
Electronic ISSN: 1433-9285
DOI
https://doi.org/10.1007/s00127-012-0586-6

Other articles of this Issue 4/2013

Social Psychiatry and Psychiatric Epidemiology 4/2013 Go to the issue